Browsing Category
Trending
Acesion Pharma receives approval for Phase I Study in Atrial Fibrillation
Acesion Pharma announces that it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the…
Read More...
Read More...
FDA approves Gilead’s Biktarvy for Treatment of HIV-1 Infection
Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a…
Read More...
Read More...
60° Pharmaceuticals (60P) receives priority review designation for Malaria Drug
60 Degrees Pharmaceuticals (60P) received Priority Review Designation from the United States Food and Drug Administration (USFDA) for Tafenoquine (TQ) for prevention of malaria in…
Read More...
Read More...
Major research project launched to crack aspirin’s anti-cancer properties
Cancer Research UK launches an international study to answer the final questions before aspirin could be recommended to reduce cancer risk.
Studies have estimated that widespread…
Read More...
Read More...
NetVation DL Medicine announces research collaboration with Pfizer Inc.
NetVation DL Medicine announced that it has entered into a two-year research collaboration with Pfizer Inc (NYSE: PFE). Under the terms of the agreement, DL Medicine will screen and…
Read More...
Read More...
Liquidia Technologies appoints Kevin Gordon as President and CFO
Liquidia Technologies announced the appointment of Kevin Gordon as President and Chief Financial Officer. Mr. Gordon will oversee finance operations and strategy, corporate development…
Read More...
Read More...
EMA accepts Teva’s Fremanezumab Marketing Authorization Application
Teva Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for fremanezumab, an anti-calcitonin gene-related…
Read More...
Read More...
Cobra Biologics and Symbiosis clinched $2.5m USD collaborative grant
International contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, Cobra Biologics and Symbiosis Pharmaceutical Services asserted having clinched…
Read More...
Read More...
Anika Therapeutics collaborates with IIB to develop MSC therapy for Osteoarthritis
Anika Therapeutics integrated orthopedic medicines company based on its proprietary hyaluronic acid ("HA") technology, today announced an agreement with the Institute of Integrative…
Read More...
Read More...
Puma Biotechnology licenses with CANbridge to commercialize NERLYNX in China
Biopharmaceutical company focused on developing Western drug candidates in China and North Asia, CANbridge Life Sciences undertakes licensing agreement to develop and commercialize…
Read More...
Read More...
FDA Commissioner vows initiatives to tackle saline shortages
As U.S is facing the wrath of flu that has become widespread in U.S, FDA continues to oversee this situation closely. FDA Commissioner, Scott Gottlieb vows to take steps to curb saline…
Read More...
Read More...
APhA and NCPO join hands to combat Opioid Abuse
The coalition, known as the National Conference of Pharmaceutical Organizations (NCPO), and American Pharmacists Association (APhA) issued a public statement seeking support from the…
Read More...
Read More...
Select Medical Holdings and Dignity Health asserts integration of Concentra and HealthWorks
Select Medical Holdings Corporation and Dignity Health asserted the completion of the transaction to combine Concentra Group with U.S HealthWorks, Inc, a subsidiary of Dignity Health …
Read More...
Read More...
Allergan asserts FDA’s approval for ssNDA for AVYCAZ
Allergan plc asserted that the U.S Food and Drug Administration has approved Allergan's supplemental New Drug Application to augment the use of AVYCAZ (ceftazidime and avibactam) to…
Read More...
Read More...
Lazarex states New FDA guidance issued
With a view to permit cancer patients access to potentially life-saving treatments, Lazarex Cancer Foundation's push for FDA issuing new FDA guidelines was taken into account by the…
Read More...
Read More...
Panacea Pharmaceuticals enrolls patient for PAN-301-1 Phase 1 Clinical Trial
Panacea Pharmaceuticals, a clinical stage bio-pharmaceutical company developing novel biologically--targeted cancer therapies and diagnostics declared the enrollment of patient in an…
Read More...
Read More...
TVA Medical’s everlinQ endoAVF System exhibits positive Clinical results
It is noteworthy that TVA Medical's everlinQ endoAVF System exhibited positive Clinical results using the everlinQ endoAVF System. An international meta-analysis of clinical experience…
Read More...
Read More...
Seattle Genetics merges with Cascadian Therapeutics
In a strategic merger revelation, Seattle Genetics and Cascadian Therapeutics signed a definitive merger agreement under which Seattle Genetics has conceded to acquire Cascadian…
Read More...
Read More...
Hisamitsu and Noven Pharma declares transdermal patch for Schizophrenia
Hisamitsu Pharmaceutical in collaboration with U.S subsidiary, Novel Pharmaceuticals, Inc declares that the the transdermal patch for the treatment of schizophrenia Development code:…
Read More...
Read More...
Vertex Pharmaceuticals selects VX-659 and VX-445 in Phase 3 for Cystic Fibrosis
Vertex Pharmaceuticals selected VX-659 and VX-445 for Phase 3 development as part of two different triple combination regimens fir people with cystic fibrosis. Phase 2 data was…
Read More...
Read More...